Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 924801 | ISIN: US09061G1013 | Ticker-Symbol: BM8
Tradegate
15.05.25 | 16:33
52,04 Euro
-0,99 % -0,52
1-Jahres-Chart
BIOMARIN PHARMACEUTICAL INC Chart 1 Jahr
5-Tage-Chart
BIOMARIN PHARMACEUTICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
52,3652,4819:52
52,3652,4819:52

Aktuelle News zur BIOMARIN PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoBioMarin Reports New Positive CANOPY Studies Data For Voxzogo294WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Monday announced new data from studies of Voxzogo in children with achondroplasia and other skeletal conditions.Voxzogo is already...
► Artikel lesen
BIOMARIN PHARMACEUTICAL Aktie jetzt für 0€ handeln
FrBioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer's Stock Picks with Huge Upside Potential3
05.05.10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know5
02.05.A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings2
02.05.BioMarin's First-Quarter Earnings & Sales Beat Estimates3
02.05.BIOMARIN PHARMACEUTICAL INC - 10-Q, Quarterly Report2
02.05.Cantor maintains BioMarin stock overweight with $90 target2
02.05.BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M4
01.05.Biomarin Pharmaceutical Inc. Q1 Profit Increases, Beats Estimates255WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) released earnings for its first quarter that increased from last year and beat the Street estimates.The company's bottom line came...
► Artikel lesen
01.05.BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report4
01.05.BioMarin Pharmaceutical Inc.: BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance85First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95...
► Artikel lesen
21.04.Oppenheimer maintains BioMarin stock Outperform with $98 target2
15.04.Spruce smartens up pipeline with deal for BioMarin asset, plans 2026 approval filing2
03.04.BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study2
02.04.BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients1
02.04.BioMarin succeeds in trial for its metabolic disorder treatment2
02.04.BioMarin's Phase 3 PEGASUS Study Of Palynziq In Adolescents With Phenylketonuria Meets Primary Goal340WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Wednesday said its Phase 3 PEGASUS study evaluating Palynziq in adolescents aged 12-17 with phenylketonuria (PKU) met its primary goal.The...
► Artikel lesen
02.04.BioMarin's PALYNZIQ shows promise for adolescents with PKU5
20.03.Citi maintains Neutral on BioMarin stock, price target at $825
20.03.BioMarin Pharmaceutical Inc.: BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO (vosoritide) in Children Under 3 with Achondroplasia at 2025 American ...239New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality...
► Artikel lesen
Seite:  Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1